Type 2 Diabetes

Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.

With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.

Exenatide extended-release represents the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for pediatric patients with type 2 diabetes.

Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.

A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.

With approval announced on July 19, HFX becomes the only spinal cord stimulation therapy approved by the FDA with a specific indication for painful diabetic neuropathy.

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers. 

A panel of experts in the treatment of diabetes discusses the importance of self-management of blood glucose levels and emphasizes the need for multidisciplinary care teams and referrals for optimal disease management.

Data show risk factors included education level and increased glucose level did not have signficant impact on BMI and body fat of children.

Analysis of more than 35,000 patients with diabetes and depressive disorder indicates patients with greater adherence to antidepressants appeared to experience fewer complications and a lower rate of mortality than those with suboptimal use.

An analysis of data from the Framingham Heart Study Offspring Cohort by investigators at the USDA Human Nutrition Research Center on Aging suggests greater consumption of whole grains was associated with a more preferable cardiometabolic risk profile than lesser consumption or consumption of refined grains.

Retinal laser photocoagulation may be performed by a specialist from a distance using telemedicine platforms.

To allow our audience to become more acquainted with our advisory board members, Endocrinology Network will be hosting a special content series highlighting our board members, their practices, and why they were invited to help guide coverage moving forward.

Key opinion leaders in endocrinology provide an overview of factors to consider when selecting or switching intranasal and injectable glucagon including ease of administration and patient preference.

Thought leaders in diabetes discuss challenges of insurance coverage for new formulations of glucagon and comment on the potential for long-term cost savings due to decreased overall healthcare system utilization.

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.

Diana Isaacs, PharmD, offers perspective on her top 5 CGM-related studies or presentations from the American Diabetes Association's 81st Scientific Sessions.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.

Despite having a favorable vote in a recent FDA AdComm meeting, Provention Bio announced the FDA has issued a CRL for teplizumab for the delay of type 1 diabetes in at-risk individuals.

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Our editorial staff has selected a shortlist of highlighted data and summary slides on their picks of the most important data to be released at the American Diabetes Association's 81st Annual Scientific Sessions.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.